Japanese company profile · 2413

M3, Inc.

In its FY2025 public filing, M3, Inc. reports Medical Platform, Evidence Solution, Career Solution, Site Solution, and 2 other reported businesses. The page shows business-level revenue and profit where the source disclosures support comparison.

Original Japanese company name: エムスリー株式会社

English company name from the issuer's official source. English company name source

Reported company-wide figures

Company revenue: ¥351.36B ↗
Company profit: ¥73.55B ↗
Profit margin: 20.9% ↗

What does this company do?

M3, Inc.'s largest reported business by revenue in FY2025 was Medical Platform.

The business with the highest reported segment profit in FY2025 was Medical Platform.

FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.

Business structure

How does it make money?

Business	Revenue from external customers	Revenue share	Segment profit (loss)
Medical Platform	¥104.04B ↗	29.6%	¥35.92B ↗
Overseas	¥86.91B ↗	24.7%	¥14.9B ↗
Patient Solution	¥56.87B ↗	16.2%	¥2.69B ↗
Site Solution	¥54.35B ↗	15.5%	¥5.77B ↗
Evidence Solution	¥24.35B ↗	6.9%	¥5.12B ↗
Career Solution	¥22.72B ↗	6.5%	¥5.92B ↗

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.

Original Japanese label

Medical Platform: メディカルプラットフォーム
Evidence Solution: エビデンスソリューション
Career Solution: キャリアソリューション
Site Solution: サイトソリューション
Patient Solution: ペイシェントソリューション
Overseas: 海外
Revenue from external customers: 外部顧客売上
Segment profit (loss): セグメント利益（損失）

Original Japanese label

Medical Platform: メディカルプラットフォーム
Evidence Solution: エビデンスソリューション
Career Solution: キャリアソリューション
Site Solution: サイトソリューション
Patient Solution: ペイシェントソリューション
Overseas: 海外
Revenue from external customers: 外部顧客売上
Segment profit (loss): セグメント利益（損失）

Reported Revenue from external customers by business over time

Fiscal year	FY2021	FY2022	FY2023	FY2024	FY2025
Medical Platform	¥83.18B	¥90.2B	¥90.49B	¥88.18B	¥104.04B
Evidence Solution	¥21.9B	¥26.53B	¥26.39B	¥24.02B	¥24.35B
Career Solution	¥13.35B	¥13.87B	¥16.61B	¥20.88B	¥22.72B
Site Solution	¥34.66B	¥34.98B	¥33.01B	¥47.03B	¥54.35B
Patient Solution	—	—	—	¥21.92B	¥56.87B
Overseas	¥51.81B	¥62.07B	¥69.85B	¥80.51B	¥86.91B

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

Business revenue growth

Company-wide revenue

Reported revenue in 2021 ¥208.16B Reported revenue in 2025 ¥351.36B

growth amount: +¥143.2B
growth annualized: +14.0%
growth total: +68.8%

FY2021–FY2025

View original filing

Overseas

Reported revenue in 2021 ¥51.81B Reported revenue in 2025 ¥86.91B

growth amount: +¥35.09B
growth annualized: +13.8%
growth total: +67.7%

FY2021–FY2025

View original filing

Career Solution

Reported revenue in 2021 ¥13.35B Reported revenue in 2025 ¥22.72B

growth amount: +¥9.37B
growth annualized: +14.2%
growth total: +70.2%

FY2021–FY2025

View original filing

This describes a reported period; it is not a forecast.

What has changed?

Not disclosed or not safely comparable in the available filings.

Source

Public filing

FY2025 · fiscal year ended March 2026

The source document may be in Japanese.

Filing ID: S100YJ25

View original filing ↗

Ask about this company

The source document may be in Japanese.